Karus is a leader in the design and development of innovative small molecule therapeutics for the treatment of cancer. The company has taken a concept-to-clinic approach, having designed and developed novel therapeutic agents from concept to early-phase clinic trials; our PI3K-p110β/δ-selective inhibitor, KA2237, is in Phase I in patients with B-cell lymphomas, and KA2507, our selective HDAC6 inhibitor, is in Phase I in patients with solid tumors.
 
We are seeking to appoint a Post-Doctoral Research Associate to work in our Research Biology team on our small molecule therapeutic programmes. The successful candidate should hold a PhD in biochemistry, molecular or cell biology, and have excellent experimental skills. Experience in performing in vitro and ex vivo assays to explore the mechanism-of-action of small molecule therapeutic agents would be beneficial, as would a background in oncology, though the latter experience is not vital. The position will be based at the company’s laboratories in Oxfordshire.

Applicants interested in this post should send their CV, and a covering letter, to info@karustherapeutics.com